Vicki Cheng

Dr. Vicki Cheng

University of British Columbia, Vancouver, British Columbia, Canada
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2022 in Current Oncology
Verified
Journal Article
Open access
PDF file
VCVicki Cheng
Vicki Cheng
NONiki Oveisi
Niki Oveisi
HMHelen McTaggart-Cowan
Helen McTaggart-Cowan
JLJonathan M Loree
Jonathan M Loree
Rachel A. MurphyRachel A. Murphy
Rachel A. Murphy
MVMary De Vera
Mary De Vera
Research suggests that colorectal cancer (CRC) is associated with mental health disorders, primarily anxiety and depression. To synthesize this evidence, we conducted a systematic review and meta-analysis of studies evaluating the onset of anxiety and depression among patients with CRC. We searched EMBASE and Medline from inception to June 2022. We included original, peer-reviewed studies that: used an epidemiologic design; included patients with CRC and a comparator group of individuals without cancer; and evaluated anxiety and depression as outcomes. We used random effects models to obtain pooled measures of associations. Quality assessment was completed using the Newcastle-Ottawa scale. Of 7326 articles identified, 8 were eligible; of which 6 assessed anxiety and depression and 2 assessed depression only. Meta-analyses showed a non-significant association between CRC and anxiety (pooled HR 1.67; 95% CI 0.88 to 3.17) and a significant association between CRC and depression (pooled HR 1.78; 95% CI 1.23 to 2.57). Predictors of anxiety and depression among patients with CRC included clinical characteristics (e.g., comorbidities, cancer stage, cancer site), cancer treatment (e.g., radiotherapy, chemotherapy, colostomy), and sociodemographic characteristics (e.g., age, sex). The impacts of anxiety and depression in patients with CRC included increased mortality and decreased quality of life. Altogether, our systematic review and meta-analysis quantified the risks and impacts of CRC on anxiety and depression, particularly an increased risk of depression after CRC diagnosis. Findings provide support for oncologic care that encompasses mental health supports for patients with CRC.

27 April 2022 in Current Oncology
Verified
Journal Article
Open access
PDF file
AHAlyssa Howren
Alyssa Howren
ESEric C. Sayre
Eric C. Sayre
VCVicki Cheng
Vicki Cheng
NONiki Oveisi
Niki Oveisi
HMHelen McTaggart-Cowan
Helen McTaggart-Cowan
MVMary De Vera
Mary De Vera
Given the increasing incidence of young-onset colorectal cancer (yCRC; <50 years), we aimed to evaluate the risk of depression and anxiety in individuals with yCRC in comparison to average-age-onset CRC (aCRC; ≥50 years) and to cancer-free controls, with stratification by sex. Our cohort study identified individuals (≥18 years) with CRC and cancer-free controls (10:1) matched on age and sex using population-based linked administrative health databases in British Columbia, Canada. We assessed depression and anxiety using validated algorithms. We evaluated the risk of depression and anxiety using multivariable Cox proportional hazard models. The cohort included 54,634 individuals with CRC (46.5% female, mean age 67.9 years) and 546,340 controls (46.5% female, mean age 67.9 years). Those with yCRC as compared to aCRC had an increased risk for depression (adjusted hazard ratio [aHR] 1.41; 95% confidence interval [CI] 1.25 to 1.60), and when stratified by sex, the risk was only significant among males (aHR 1.76; 95% CI 1.48 to 2.10). When comparing individuals with yCRC to cancer-free controls, the overall risk of depression (aHR 1.00; 95% CI 0.92 to 1.10) and anxiety (aHR 1.10; 95% CI 0.95 to 1.27) was non-significant; however, males had a significantly higher risk for mental health disorders, specifically depression (aHR 1.17; 95% CI 1.03 to 1.33). Altogether, our findings that individuals with yCRC experience higher risk of depression compared to those with aCRC as well as cancer-free controls, particularly among males, suggest effects of age and sex on mental health outcomes.

22 March 2024 in Current Oncology
Verified
Journal Article
Open access
PDF file
NONiki Oveisi
Niki Oveisi
VCVicki Cheng
Vicki Cheng
DTDani Taylor
Dani Taylor
HBHaydn Bechthold
Haydn Bechthold
MBMikaela Barnes
Mikaela Barnes
MVMary De Vera
Mary De Vera
Over the last two decades, patient engagement in cancer research has evolved significantly, especially in addressing the unique challenges faced by adolescent and young adult (AYA) cancer populations. This paper introduces a framework for meaningful engagement with AYA cancer patient research partners, drawing insights from the “FUTURE” Study, a qualitative study that utilizes focus groups to explore the impact of cancer diagnosis and treatment on the sexual and reproductive health of AYA cancer patients in Canada. The framework’s development integrates insights from prior works and addresses challenges with patient engagement in research specific to AYA cancer populations. The framework is guided by overarching principles (safety, flexibility, and sensitivity) and includes considerations that apply across all phases of a research study (collaboration; iteration; communication; and equity, diversity, and inclusion) and tasks that apply to specific phases of a research study (developing, conducting, and translating the study). The proposed framework seeks to increase patient engagement in AYA cancer research beyond a supplementary aspect to an integral component for conducting research with impact on patients.

10 March 2023 in Cancers
Verified
Journal Article
Open access
PDF file
NONiki Oveisi
Niki Oveisi
VCVicki Cheng
Vicki Cheng
UEUrsula Ellis
Ursula Ellis
Stuart PeacockStuart Peacock
Stuart Peacock
HMHelen McTaggart-Cowan
Helen McTaggart-Cowan
MVMary De Vera
Mary De Vera
Background: This systematic review and meta-analysis (SRMA) aimed to synthesize the current literature on the impacts of adolescent and young adult (AYA, ages 15–39 years) cancer on reproductive health outcomes. Methods: EMBASE and Medline were searched from 1 January 2000 to 26 January 2022 for observational studies that included individuals with AYA cancer and controls which evaluated reproductive health outcomes. We used random effects models and 95% confidence intervals to obtain pooled measures of associations between AYA cancer, cancer treatment, and reproductive health outcomes. Results: The search identified 8625 articles; 21 were included. 62 reproductive outcomes were assessed and classified according to a sex-based framework as fetal/neonatal (n = 26), maternal (n = 11), fetal/neonatal-maternal (n = 23), and maternal-paternal (n = 2). Meta-analyses of crude estimates showed significant associations between AYA cancer and outcomes including preterm birth (pooled odds ratio [pOR] 1.31; 95% CI: 1.22, 1.42), gestational diabetes (pOR 1.43; 95% CI: 1.03, 1.99), and fertility treatment (pOR 2.66; 95% CI 1.71, 4.11). We also found higher odds of preterm birth (pOR 1.65; 95% CI: 1.21, 2.26) and low APGAR score at birth (pOR 2.03; 95% CI: 1.32, 3.13) among AYA cancer patients who received radiation compared to controls. Conclusions: Our SRMA quantified impacts of AYA cancers and treatments on several reproductive health outcomes.

10 December 2021 in Journal of Medical Internet Research
Verified
Journal Article
Open access
ECErina Chan
Erina Chan
SSSerena S Small
Serena S Small
MWMaeve E Wickham
Maeve E Wickham
VCVicki Cheng
Vicki Cheng
EBEllen Balka
Ellen Balka
CHCorinne M Hohl
Corinne M Hohl
Background: Existing systems to document adverse drug events often use free text data entry, which produces nonstandardized and unstructured data that are prone to misinterpretation. Standardized terminology may improve data quality; however, it is unclear which data standard is most appropriate for documenting adverse drug event symptoms and diagnoses. Objective: This study aims to compare the utility, strengths, and weaknesses of different data standards for documenting adverse drug event symptoms and diagnoses. Methods: We performed a mixed methods substudy of a multicenter retrospective chart review. We reviewed the research records of prospectively diagnosed adverse drug events at 5 Canadian hospitals. A total of 2 pharmacy research assistants independently entered the symptoms and diagnoses for the adverse drug events using four standards: Medical Dictionary for Regulatory Activities (MedDRA), Systematized Nomenclature of Medicine (SNOMED) Clinical Terms, SNOMED Adverse Reaction (SNOMED ADR), and International Classification of Diseases (ICD) 11th Revision. Disagreements between research assistants regarding the case-specific utility of data standards were discussed until a consensus was reached. We used consensus ratings to determine the proportion of adverse drug events covered by a data standard and coded and analyzed field notes from the consensus sessions. Results: We reviewed 573 adverse drug events and found that MedDRA and ICD-11 had excellent coverage of adverse drug event symptoms and diagnoses. MedDRA had the highest number of matches between the research assistants, whereas ICD-11 had the fewest. SNOMED ADR had the lowest proportion of adverse drug event coverage. The research assistants were most likely to encounter terminological challenges with SNOMED ADR and usability challenges with ICD-11, whereas least likely to encounter challenges with MedDRA. Conclusions: Usability, comprehensiveness, and accuracy are important features of data standards for documenting adverse drug event symptoms and diagnoses. On the basis of our results, we recommend the use of MedDRA.

24 February 2025 in Arthritis Care & Research
Verified
Journal Article
Open access
VCVienna Cheng
Vienna Cheng
NANeda Amiri
Neda Amiri
VCVicki Cheng
Vicki Cheng
UEUrsula Ellis
Ursula Ellis
JCJacquelyn J. Cragg
Jacquelyn J. Cragg
MVMary De Vera
Mary De Vera
Objective: Targeted synthetic disease‐modifying antirheumatic drugs (tsDMARDs) have expanded the management of autoimmune diseases, including rheumatic diseases. As the use of these drugs grows, it is important to understand their effects on pregnancy. We conducted a scoping review to synthesize the current evidence on the impacts of tsDMARDs on pregnancy outcomes.Methods: We searched the Embase, MEDLINE, and CENTRAL databases in November 2023. We included studies that examined tsDMARD exposure for chronic autoimmune disease(s), particularly in mothers during pregnancy, fathers before conception, and/or fetuses/neonates in utero. We extracted data on sample size, study design, tsDMARD exposure (dose and duration), and reproductive health outcomes.Results: Of 6,712 studies screened, eight were included, namely nine case reports, one case series, four cross‐sectional studies, and one cohort study among patients with ulcerative colitis, rheumatoid arthritis, and psoriasis. Sample sizes ranged from 1 to 116 pregnancies or offspring, with six studies on tofacitinib, one on baricitinib, one on upadacitinib, and no studies on apremilast. Overall, 19 fetal/neonatal outcomes, six fetal/neonatal‐maternal outcomes, and three maternal outcomes were extracted. The most frequently reported fetal/neonatal outcomes were congenital anomaly (n = 4), preterm birth (n = 4), and the fetal/neonatal‐maternal outcome of spontaneous abortion (n = 4). Only one study reported on the maternal outcome of delivery via Cesarean section.Conclusion: Our scoping review of evidence to date on the perinatal use of tsDMARDs reveal small sample sizes and a limited number of studies, all largely descriptive in nature. Findings highlight evidence gaps that preclude providers and patients from making informed decisions when considering the perinatal use of tsDMARDs. image